FIELD: medicine.
SUBSTANCE: invention relates to the fluorescent method for chemotherapy efficiency prediction in children with acute lymphoblastic leukemia by determining the ATP concentrations in mitochondria, for which blood sampling is performed before and after chemotherapy, a fluorescent macro biomarker of chemotherapy efficiency is isolated, where macro biomarker is the ATP concentration in blood cells mitochondria, which is determined automatically, using a laser confocal microscope, through macro biomarker fluorescence intensity recording.
EFFECT: invention provides assessment of chemotherapy efficiency, in particular the emergence of hepatotoxic effects and drug resistance during chemotherapy in children with acute lymphoblastic leukemia.
1 ex
| Title | Year | Author | Number |
|---|---|---|---|
| FLUORESCENT METHOD FOR CHEMOTHERAPY EFFICIENCY PREDICTION IN CHILDREN WITH ACUTE LYMPHOBLASTIC LEUKEMIA | 2016 |
|
RU2647834C2 |
| METHOD FOR PREDICTION OF CLINICAL EFFECTIVENESS IN THE PATIENTS WITH ACUTE MYELOBLASTIC LEUKEMIAS WITH ANTI-TUMOR PREPARATIONS DAUNORUBICIN AND CYTOSINE-ARABINOSIDE | 2019 |
|
RU2702657C1 |
| FERRITIN NANOPARTICLES CONTAINING CHEMOTHERAPEUTIC AGENT | 2019 |
|
RU2810594C2 |
| PREDICTION OF RESPONSE TO ALVICIDIB BY ANALYSIS OF MITOCHONDRION PROFILE | 2016 |
|
RU2717829C2 |
| COMBINATION OF SIROSINGOPIN AND MITOCHONDRIAL INHIBITORS FOR TREATMENT OF CANCER AND FOR IMMUNOSUPPRESSION | 2012 |
|
RU2602937C2 |
| RECEPTOR TARGETING CONSTRUCTS AND USES THEREOF | 2015 |
|
RU2682335C2 |
| PHARMACEUTICAL COMPOSITION BASED ON TRIINDOLYLMETHANE DERIVATIVE AS ANTI-TUMOUR MEDICATION | 2012 |
|
RU2549430C2 |
| RAPID METHOD FOR DETERMINING RISK OF CELL MALIGNANCY | 2012 |
|
RU2508542C1 |
| METHOD FOR DETERMINING INDIVIDUAL RESPONSIVENESS OF HUMAN MITOCHONDRIA UNDER ACTION OF METABOLIC PREPARATIONS IN TESTS in vitro | 2014 |
|
RU2578436C1 |
| HUMAN T-LYMPHOBLASTIC LEUCEMIA A4 CELL LINE USEFUL IN SCREENING OF ANTITUMOR AGENTS | 2004 |
|
RU2267532C1 |
